Osteonecrosis
is a medical term meaning "bone death." It is caused by an
inflammation of the hip joint due to a reduction in blood supply. This type of
bone disease can have an extensive impact on the quality of life of individuals
suffering from it, making the treatment of osteonecrosis extremely important.
Market Dynamics
High
prevalence of osteonecrosis is expected to propel growth of the osteonecrosis
treatment market. For instance, according to the study, ‘Epidemiology of
osteonecrosis among older adults in Sweden’, published in Springer in January
2019, the 10-year risk of osteonecrosis was 0.4% and the incidence rate was 4.7
cases/10000 person-years. Moreover, high prevalence of osteoporosis is also
expected to aid in growth of the osteonecrosis treatment market. For instance,
according to a study published online in February 2020 in the Journal of
Clinical Endocrinology & Metabolism, for denosumab-treated women with
postmenopausal osteoporosis, invasive oral procedures and events (OPEs),
including dental implants, tooth extraction, natural tooth loss, scaling/root
planning, and jaw surgery, are common and associated with osteonecrosis of the
jaw.
High
prevalence of cancer is expected to offer lucrative growth opportunities for
players in the osteonecrosis
treatment market. For instance, in December 2020, a study by researchers
from the SWOG Cancer Research Network, a cancer clinical trials group funded by
the National Cancer Institute (NCI), part of the National Institutes of Health
(NIH), and published in JAMA Oncology, found that 2.8 percent of patients on
average develop osteonecrosis of the jaw, within three years of starting a
common treatment for cancer that has spread to the bone. Moreover, increasing
geriatric population is also expected to aid in growth of the market. For
instance, according to the U.S. Census Bureau, the U.S. geriatric population is
expected to reach 77 million by 2034.
Among
regions, North America is expected to witness significant growth in the osteonecrosis
treatment market, owing to high prevalence of cancer. For instance, according
to the American Cancer Society, in 2019, there will be an estimated 1,762,450
new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Competitive Analysis
Major
players operating in the osteonecrosis treatment market include, Bone Health, Bone
Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd.
Major
players operating in the osteonecrosis treatment market are focused on approval
and launch of new products to expand their product portfolio. For instance, in
December 2020, Bone Health’s OsteoBoost received the U.S FDA’s Breakthrough
Device Designation to reduce the risk of osteoporosis.
Comments
Post a Comment